BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

...backs Protomer Protomer Technologies Inc. has received an investment of an undisclosed amount from the JDRF T1D Fund...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...B led by Forbion, with participation from Fonds de solidarité FTQ and existing investors Genesys, JDRF T1D Fund...
BioCentury | Jul 29, 2020
Finance

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

...of principle in animal models were the impetus for the new financing round. Existing investors JDRF T1D Fund...
BioCentury | Jun 18, 2020
Finance

June 17 Quick Takes: Constellation, Celldex raise follow-ons; plus CureVac quiet on IPO chatter and venture cash for GreenLight, TILT, DiogenX

...company DiogenX has raised €4.5 million from Advent France Biotechnology, Boehringer Ingelheim Venture Fund and JDRF T1D Fund...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...outside of oncology. Repertoire announced March 25 it had received an undisclosed investment from the JDRF T1D Fund...
...David Berry, Doug Cole, Ewen Cameron Funds raised: At least $220 million Investors: Flagship Pioneering, JDRF T1D Fund...
BioCentury | May 18, 2020
Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

...its total of private capital raised to $167 million. Existing investors GV, Illumina Ventures, Invus, JDRF T1D Fund...
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

...i2O Therapeutics Inc. raised $4 million in a seed round led by Sanofi Ventures and JDRF T1D Fund...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

...the round, as did existing investors Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, JDRF T1D Fund...
BioCentury | Mar 2, 2020
Finance

Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

...and the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359), as well as JDRF T1D Fund...
Items per page:
1 - 10 of 35
BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

...backs Protomer Protomer Technologies Inc. has received an investment of an undisclosed amount from the JDRF T1D Fund...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...B led by Forbion, with participation from Fonds de solidarité FTQ and existing investors Genesys, JDRF T1D Fund...
BioCentury | Jul 29, 2020
Finance

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

...of principle in animal models were the impetus for the new financing round. Existing investors JDRF T1D Fund...
BioCentury | Jun 18, 2020
Finance

June 17 Quick Takes: Constellation, Celldex raise follow-ons; plus CureVac quiet on IPO chatter and venture cash for GreenLight, TILT, DiogenX

...company DiogenX has raised €4.5 million from Advent France Biotechnology, Boehringer Ingelheim Venture Fund and JDRF T1D Fund...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...outside of oncology. Repertoire announced March 25 it had received an undisclosed investment from the JDRF T1D Fund...
...David Berry, Doug Cole, Ewen Cameron Funds raised: At least $220 million Investors: Flagship Pioneering, JDRF T1D Fund...
BioCentury | May 18, 2020
Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

...its total of private capital raised to $167 million. Existing investors GV, Illumina Ventures, Invus, JDRF T1D Fund...
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

...i2O Therapeutics Inc. raised $4 million in a seed round led by Sanofi Ventures and JDRF T1D Fund...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

...the round, as did existing investors Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, JDRF T1D Fund...
BioCentury | Mar 2, 2020
Finance

Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

...and the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359), as well as JDRF T1D Fund...
Items per page:
1 - 10 of 35